Evidence map›Paper›PMID 39757626›Full record

ReviewCurrent Alzheimer research2024

Advances in Alzheimer's Disease Biomarkers.

Kuan Li, Yujie Gao, Muxi Liu, Yizhao Chen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current Alzheimer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kuan LiDepartment of Neurosurgery, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, Guangzhou, China.ORCID 0000-0001-7662-3093
Yujie GaoDepartment of Neurosurgery, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, Guangzhou, China.ORCID 0009-0004-0698-1337
Muxi LiuDepartment of Arts and Social Science, Philosophy Faculty, University of Zurich, Zurich, Switzerland.ORCID 0009-0005-3483-5027
Yizhao ChenDepartment of Neurosurgery, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, Guangzhou, China.ORCID 0000-0002-5052-4406

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative condition characterized by gradual onset and complex pathological mechanisms. Clinically, it presents with progressive cognitive decline and behavioral impairments, making it one of the most common causes of dementia. The intricacies of its pathogenesis are not fully understood, and current treatment options are limited, with diagnosis typically occurring at intermediate to advanced stages. The development of new biomarkers offers a crucial avenue for the early diagnosis of AD and improving patient outcomes. Several biomarkers with high specificity have been identified. This article reviews biomarkers related to tau protein, β-amyloid, and blood cells to deepen our understanding of AD and emphasize the advantages and disadvantages of various biomarkers in order to explore further and mine new biomarkers for AD diagnosis.

Indexed as

Alzheimer DiseaseBiomarkersAmyloid beta-PeptidesHumanstau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer's diseasebehavioral impairments.biomarkersblood cellstau proteinβ-amyloid

Identifiers

PMID39757626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.